Is Sinovac Biotech Ltd. (NASDAQ: SVA) living on borrowed time?


Here is a look at the scorecard of Sinovac Biotech Ltd. (NASDAQ:SVA) for the most recent quarter as well as analyst estimates for the coming periods.

The company generated sales of 28.74M%, implying an increase of 0.42%% compared to a similar quarter a year earlier. The revenue growth accelerated/decelerated by grow%.

To achieve the reported sales of 28.74M% for the quarter, the company incurred $5.71M in cost of goods. Therefore, after taking into account the cost of sales, Sinovac Biotech Ltd. emerged with a gross income of $23.03M.

Recently, Sinovac Biotech Ltd. (NASDAQ:SVA) announced that as a result of support from new investors and existing shareholders it had raised $1,500,000.

Let?s look into the technical of the stock

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend. The market is approaching oversold territory. Be watchful of a trend reversal.

Sinovac Biotech Ltd. also incurred other expenses in the course of operation. So after taking those into account as well, it exited the quarter with EPS of $0.06. The company had 57.02M diluted outstanding shares at the end of the quarter.

For the next quarter, analysts on the average are modeling EPS of $.

Sinovac Biotech Ltd.?s cash balance at the end of the most recent quarter was 54.63M%. The company generated free cash flow of $(4.8M) during the quarter, with net operating cash flow being $(1.19M). Net change in cash was $3.81M.

That said, Sinovac Biotech Ltd. finished the quarter with debt of 31.84M%. The debt increased/fell by growing from the past period.

What is Wall Street thinking about Sinovac Biotech Ltd.? To put the analyst recommendation into perspective, recommendation in the range of 1.00 – 1.24 implies a BUY recommendation, while 1.25 – 1.74 implies OVERWEIGHT. HOLD recommendation is represented by 1.75 – 2.24, UNDERWEIGHT is represented by 2.25 – 2.74 while SELL is represented by 2.75 – 3.00.

Does Sinovac Biotech Ltd. have a healthy balance sheet? A look at the company?s balance sheet at the end of the most recent quarter shows that it reflects total assets of $203.72M, offset by total liabilities of $72.76M.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.